A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

ABSTRACT: The objective is to investigate the efficacy and safety of two-weekly alternative regimen of Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer.

DISEASE(S): Colorectal Neoplasms,Advanced Colorectal Cancer

PROVIDER: 2334327 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR